Article Per Year (5 Year)
p-Index From 2021 - 2026
1.784
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Udayana Pharmaciana: Jurnal Kefarmasian Althea Medical Journal Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya Berkala Ilmiah Kedokteran Duta Wacana JKKI : Jurnal Kedokteran dan Kesehatan Indonesia eJournal Kedokteran Indonesia MEDICINUS Acta Neurologica Indonesia
Rizaldy Taslim Pinzon
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 30 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search
Journal : MEDICINUS

 1 
Terapi Tambahan Predimenol pada Osteoartritis: Serial Laporan Kasus Rizaldy Taslim Pinzon
MEDICINUS Vol. 37 No. 1 (2024): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/wdj43n05

Abstract

Osteoartritis merupakan suatu kelainan muskuloskeletal yang dapat menyebabkan penurunan kualitas hidup dan terganggunya aktivitas hidup sehari-hari (activities of daily living/ADL). Degenerasi sendi yang terjadi pada osteoartritis dapat menimbulkan beberapa manifestasi klinis seperti nyeri, bengkak, kaku, dan terbatasnya pergerakan pada sendi, yang menyebabkan penderita osteoartritis mengalami hambatan dalam menjalani aktivitas sehari-hari. Tulisan ini melaporkan serial kasus pasien osteoartritis KL2−KL3 dengan berbagai penyakit penyerta. Terapi awal yang diberikan adalah paracetamol 500 mg tiga kali sehari yang dikombinasikan dengan terapi tambahan predimenol 200 mg dua kali sehari. Pada observasi yang dilakukan setelah terapi selama dua minggu, kami mengamati perbaikan yang signifikan dalam penurunan intensitas nyeri dan mobilitas. Predimenol juga dilaporkan dapat ditoleransi dengan baik pada semua pasien.
The Use of Predimenol After Simple Pain Intervention in High-Risk Patients: A Case Series Rizaldy Taslim Pinzon; Aditya Aristo Marvel Nugroho
MEDICINUS Vol. 38 No. 1 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/4fb0jj22

Abstract

Effective pain management is a common challenge in clinical practice, whether it involves prescription medications or over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs). The use of NSAIDs has been linked to various risks, including cardiovascular (CV), kidney, and gastrointestinal (GI) complications. Certain group of patients face a higher likelihood of these risks. NSAIDs consumptions have been shown to cause a modest, but steady increase in the chance of experiencing CV events and developing kidney problems. In this case series, we reported a series of inflammatory pain cases. Following simple pain intervention, we administered paracetamol and Predimenol over a 10 day period. The use of Predimenol was proven to be effective in alleviating pain without causing any notable adverse effects. 
The Benefit of DLBS3233 as Add-on Therapy for Symptomatic Painful Diabetic Neuropathy: Case Series Rizaldy Taslim Pinzon; Abraham Al Jody; Nicholas Adriel Pinzon
MEDICINUS Vol. 38 No. 2 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/rhjkcb40

Abstract

Symmetrical painful diabetic neuropathy (PDN) is a highly prevalent form of diabetic peripheral neuropathy with significant morbidity. Despite its high prevalence, the optimal treatment of this condition remains a clinical challenge. There was an emergence need for add-on therapy that more focused on the dimensions of inflammation and toxic oxidative stress.Previous evidences from placebo-controlled studies have shown that opioids, antiepileptic, and antidepressant drugs are effective for alleviating PDN symptoms. In many cases, safety issues regarding potential side effects of those drugs limit the optimal use of the medications. We report case series of painful diabetic neuropathy in type 2 diabetic patients. DLBS3233 was given as add-on therapy to standard oral antidiabetic medication or insulin and adjuvant analgesics for all patients. After 3 months follow up, there was modest pain reduction and improvement in blood glucose control in allpatients. DLBS3233 was well tolerated in all patients. 
The Use of Predimenol for Nonspecific, Mild-to-Moderate Headache: Case Series Rizaldy Taslim Pinzon; Andre Darmawan Wiyono
MEDICINUS Vol. 38 No. 3 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/s2zpt094

Abstract

Headache is a major healthcare concern worldwide. Adequate headache management is a widespread clinical concern, either using prescription or over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs). The use of NSAIDs for headache has been associated with several risk of cardiovascular (CV), renal, and gastrointestinal (GI) complications.There were certain patients are at increased risk of using these agents. The use of NSAIDs results in small but consistent increases in the risk of cardiovascular events and kidney problem. We report case series of primary headache conditions with GI comorbidities. After careful history taking, neurological examination, and imaging, we used paracetamol and Predimenol for one week. The use of Predimenol was effective in reducing headache severity without any significant side effects. 
The Gastroprotective Effect of DLBS2411 for High-Risk Gastrointestinal Patients: Case Series in Inflammatory Pain Condition Rizaldy Taslim Pinzon; Abraham Al Jody; Nicholas Adriel Pinzon
MEDICINUS Vol. 38 No. 4 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/6197xj25

Abstract

Chronic pain is a common and distressing problem for the population. The cyclooxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in managing acute and chronic pain. Research has provided a greater understanding of the risks of gastrointestinal, cardiovascular, and renal events associated with NSAID use. Proton pump inhibitors (PPIs) are widely prescribed due to their gastroprotective effects in NSAID users. However, PPIs also have several acid-inhibition-related and unrelated adverse effects that limit their use in high-risk patients. We report five patients suffering from painful inflammatory pain (flare rheumatoid arthritis, painful knee bursitis, and osteoarthritis). In this case series we evaluate the use of DLBS2411 as an alternative to PPIs. Our study suggests that DLBS2411 can be a safe alternative to PPIs for gastrointestinal high-risk patients who require anti-inflammatory agents.
The Benefit of DLBS1033 for Deep Vein Thrombosis in A Hemorrhagic Stroke Patient: A Case Report Rizaldy Taslim Pinzon; Ivana Prasetianingtyas
MEDICINUS Vol. 38 No. 10 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/yvsv1k10

Abstract

Background: Deep vein thrombosis (DVT) is a significant complication in patients with hemorrhagic stroke, primarily due to prolonged immobility. Although anticoagulants are routinely used for DVT prophylaxis in stroke patients, its application in hemorrhagic stroke remains controversial due to the increased risk of intracranial bleeding. This resulting in a challengingbalance between preventing DVT and avoiding further hemorrhage. DLBS1033, a bioactive protein fraction from the earthworm Lumbricus rubellus, demonstrated antithrombotic, thrombolytic, and antiplatelet aggregation activities, offeringa potential alternative therapeutic approach in such cases.Case report: A 68-year-old male with history of chronic hypertension and well-controlled type 2 diabetes mellitus presented to the emergency department with drowsiness and left-sided hemiparesis, subsequently diagnosed as intracerebral hemorrhage. On the sixth day of hospitalization, the patient developed DVT. DLBS1033 was administered as part of themanagement strategy.Conclusions: This case report demonstrates the effective and safe use of DLBS1033 in managing DVT for patient with hemorrhagic stroke. DLBS1033 is considered a potential promising agent for treating thrombus-related diseases.
Co-Authors Abraham Al Jody Adi Utarini Aditya Aristo Marvel Nugroho Aditya Batlajery Alfajri, Novi Zain Andre Darmawan Wiyono Caecilia Lelia Rahmawati Daniel Mahendra Krisna Daniel Mahendra Krisna Diah Mutiarasari Dyah Wulaningsih Retno Edi Edenia Asisaratu Eka Ari Wibawa Erna Kristin Esdras Ardi Pramudita Florence Florence Gavrila, Priska Gian Gunadi Gunadi Hardi Astuti Witasari Hariatmoko . Hariatmoko Hariatmoko Ivana Prasetianingtyas Ivana Purnama Dewi Jerry Tanhardjo Kadek Reisya Sita Damayanti Kristina Reny Indriawati Kriswanto Widyo Larasati, Yutta Lisa Kurnia Sari Maria Silvia Merry Nicholas Adriel Pinzon Nunki Puspita Utomo Pudji Sri Rasmiati Sugianto Sugianto Tiara Kusumaningtyas Tiara Triasari Tjahjono Kuntjoro Trisasi Lestari Vincent Exel Susanto Yohana Puji Dyah Utami